for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Jiangsu Hengrui Medicine Co Ltd

600276.SS

Latest Trade

88.98CNY

Change

-3.62(-3.91%)

Volume

33,272,090

Today's Range

88.03

 - 

93.65

52 Week Range

41.48

 - 

96.47

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Jiangsu Hengrui Medicine's 9-Mth Net Profit Up 28.3% Y/Y

Oct 24 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS 9-MONTH NET PROFIT UP 28.3% Y/Y AT 3.7 BILLION YUAN ($523.83 million).

Jiangsu Hengrui Medicine Says H1 Net Profit Up 26.3% Y/Y

Aug 29 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS H1 NET PROFIT UP 26.3% Y/Y.

Jiangsu Hengrui Medicine's 2018 Net Profit Up 25.61 Percent Y/Y 1.19 Billion Yuan

April 16 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS ITS 2018 NET PROFIT UP 25.61 PERCENT Y/Y AT 1.19 BILLION YUAN ($177.32 million).

Jiangsu Hengrui Medicine Says Its 2018 Net Profit Up 26.4 Percent Y/Y

Feb 15 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS ITS 2018 NET PROFIT UP 26.4 PERCENT Y/Y AT 4.065 BILLION YUAN ($600.38 million).

Jiangsu Hengrui Medicine Says 9-Month Net Profit Up 25.1 Percent Y/Y

Oct 25 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS 9-MONTH NET PROFIT UP 25.1 PERCENT Y/Y.

Jiangsu Hengrui Medicine's H1 Net Profit Up 21.4 Percent Y/Y At 1.9 Billion Yuan

Aug 9 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS H1 NET PROFIT UP 21.4 PERCENT Y/Y AT 1.9 BILLION YUAN ($278.34 million).

Jiangsu Hengrui Medicine to merge with wholly owned medicine unit

July 12 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it will merge with a Jiangsu-based wholly owned medicine unit .Says the unit will be dissolved after merger .

Jiangsu Hengrui Medicine to pay A shares div for FY 2017 on May 30

May 24 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS> ::* Says it will pay cash dividend of 0.13 yuan(before tax)/share and distribute 0.2 stock dividend/share as well as use additional paid-in capital to distribute 0.1 new shares for every share for 2017 to shareholders of record on May 29.* The company's shares will be traded ex-right and ex-dividend on May 30 and the dividend will be paid on May 30.

Jiangsu Hengrui Medicine passes FDA approval

May 21(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received approval for fondaparinux sodium injection (product) from U.S Food and Drug Administration .Company will be able to sell the product in the U.S. after receiving the FDA approval.

Jiangsu Hengrui Medicine passes FDA approval

May 10 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received approval for its drug Thiotepa for injection, which is used for treatment of breast cancer, ovarian cancer and other lymphoma, from U.S Food and Drug Administration .

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up